Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

PEG-MGF: Mechanism of Action

PEG-MGF is a pegylated synthetic analogue of mechano growth factor (MGF), the IGF-1Ec splice variant of the IGF-1 gene. This page sets out the mechanism of action as it appears in the research literature, and states plai

peptides-pro Editorial

PEG-MGF is a pegylated synthetic analogue of mechano growth factor (MGF), also written mechano-growth factor and known in the literature as IGF-1Ec, the mechanosensitive splice variant of the insulin-like growth factor 1 (IGF-1) gene. It belongs to the IGF-1 analogue class of research peptides, the same broad family that includes IGF-1 itself and the GH fragment AOD9604 (hGH 176-191) in surveys of compounds encountered in self-administration protocols [1]. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight for PEG-MGF, so none is stated here. The defining structural feature is the polyethylene glycol (PEG) moiety attached to the peptide, a modification used in the wider peptide field to alter the pharmacokinetic profile of a parent molecule; the same pegylation strategy appears in the clinical literature as PEG-rhGH, pegylated recombinant human growth hormone, studied in children with Turner syndrome [8].

The pathway the work centres on is the GH-IGF-1 axis, and within it the IGF-1 receptor and IGF-1 signalling. Mechano growth factor is a splice variant of IGF-1, so the mechanistic questions asked of it are the questions asked of IGF-1 signalling: receptor binding, downstream anabolic and proliferative signalling, and the tissue-specific context in which the variant is expressed.

Research Studies

PEG-MGF and the IGF-1Ec splice variant

MGF is not a separate gene product. It is an alternatively spliced transcript of the IGF-1 gene, and the literature refers to it as IGF-1Ec. The mechanistic interest in the variant comes from its expression pattern rather than from a distinct receptor: the peptide acts through IGF-1 receptor signalling, and the splice variant is described as mechanosensitive, meaning its expression is associated with mechanical loading of tissue. PEG-MGF is the pegylated form of that sequence, and the pegylation is the modification that distinguishes the research reagent from the unmodified peptide.

Because the evidence block for this page does not contain primary in vitro binding data, receptor affinity constants or signalling cascade measurements for PEG-MGF specifically, those values are not reported here. What can be stated is the class position: PEG-MGF sits within the IGF-1 analogue group, and the mechanistic framework applied to it is IGF-1 receptor-mediated signalling.

PEG-MGF and the GH-IGF-1 axis as a research category

Surveys of performance-enhancing peptides describe a set of agents marketed as research compounds that are intended to modulate the GH-IGF-1 axis [1]. That set includes GHRH analogues such as sermorelin, tesamorelin, CJC-1295 with and without the Drug Affinity Complex, and growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin, alongside the GH fragment AOD9604 and IGF-1 analogues [1]. PEG-MGF belongs to the IGF-1 analogue end of that list rather than the secretagogue end: it is not a releasing-factor analogue and does not act by stimulating endogenous GH release. The mechanistic distinction matters when reading the literature, because the two ends of the axis are studied with different endpoints.

PEG-MGF and pegylation as a pharmacokinetic strategy

Pegylation is a modification applied across the peptide field, and the clearest clinical example in the supplied evidence is PEG-rhGH, pegylated recombinant human growth hormone, studied in children with Turner syndrome to explore optimal dosing and to provide evidence for a Phase 3 trial design [8]. That study is not a study of PEG-MGF, and no result from it should be read across to PEG-MGF. It is cited here only because it establishes that pegylation of a GH-axis peptide is a strategy that has been taken into clinical research in a paediatric population, with safety and efficacy as the stated evaluation points [8].

CompoundClass position on the GH-IGF-1 axisEvidence context in the supplied block
PEG-MGFIGF-1 analogue; pegylated MGF (IGF-1Ec)No primary study data in the supplied evidence block
PEG-rhGHPegylated recombinant human growth hormoneClinical study in children with Turner syndrome [8]
GHRH analogues and GH secretagoguesReleasing-factor analogues and secretagoguesNamed in a survey of compounds marketed as research compounds [1]

PEG-MGF and the regulatory status of research-compound peptides

The survey that names the GH-IGF-1 axis agents describes them as unregulated peptides marketed as research compounds and intended to modulate the axis [1]. That description is a statement about the market and regulatory category, not about mechanism. For a mechanism page the relevant point is that the category label does not carry efficacy data with it: a compound being sold as a research compound tells the reader nothing about whether its mechanism has been characterised in controlled studies.

PEG-MGF and the limits of the supplied evidence

The evidence block assembled for this page does not contain a study of PEG-MGF in any model. It contains a survey that places IGF-1 analogues within the GH-IGF-1 axis category [1], a clinical study of pegylated recombinant human growth hormone in Turner syndrome [8], and a set of clinical trial records in unrelated indications. No animal-model data and no in vitro data specific to PEG-MGF are present in the block, so no such data are reported here. Where a reader encounters claims about PEG-MGF in cell culture or in rodent models, those claims are not sourced from the evidence supplied for this page.

PEG-MGF and the unrelated clinical records in the evidence block

Several records in the supplied evidence concern indications with no mechanistic connection to the GH-IGF-1 axis. These include a trial of trontinemab in early symptomatic Alzheimer's disease [2], a pre-screening study for Alzheimer's disease trial eligibility [3], the EVOKE and EVOKE Plus studies of semaglutide in early Alzheimer's disease [4][5], a study of lipoprotein(a) epidemiology in patients with established cardiovascular disease [6], and the THALES study of ticagrelor and ASA after acute stroke or transient ischaemic attack [7]. They are listed here for completeness of the source set and are not evidence about PEG-MGF. None of them should be cited in support of a mechanism claim for this compound.

PEG-MGF and what a mechanism page can and cannot establish

A mechanism page can state the class, the parent molecule, the splice variant identity and the receptor family. For PEG-MGF, that means: pegylated synthetic analogue of mechano growth factor, the IGF-1Ec splice variant of the IGF-1 gene, acting within IGF-1 receptor signalling on the GH-IGF-1 axis. A mechanism page cannot establish potency, half-life, tissue selectivity or downstream effect magnitude without primary data, and the supplied evidence block does not provide those data for PEG-MGF. The honest position is that the mechanism is described at the level of class and pathway, and the quantitative characterisation is absent from the sources available here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and it is not a medicine, a supplement or a therapeutic product. We do not provide dosing information, administration guidance or medical advice of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp